Merck drug extends survival in endometrial cancer trial, wins U.S. priority review
Merck’s targeted cancer drug sac-TMT extends survival in endometrial cancer, prompting US priority review and potential approval by 2027.
The Hindu asks for a subscription to read the full story. If you have one, sign in on their site.
0 comments